Piper Sandler lowered the firm’s price target on CytomX Therapeutics (CTMX) to $3.25 from $3.50 and keeps an Overweight rating on the shares following Q3 results. Cash of $118M provides runway to end of 2025, so a bit tight, but excludes any future potential milestones, Piper told investors in a research note.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.